Search research articles
Contact Us
Filters
Showing results (91-100 of 145) with videos related to
Page
of 15
Sort By:
Heart, Lung & Circulation
|
April 3, 2024
2024 Australia-New Zealand Expert Consensus Statement on Cardiac Amyloidosis
Nicole K Bart, Diane Fatkin, James Gunton, et al.
The Clinical Biochemist. Reviews
|
July 26, 2021
Report of the Survey Conducted by RCPAQAP on Current Practices for Beta-Migrating Paraprotein Reporting
Joel D Smith, Nilika Wijeratne, Hans G Schneider, et al.
European Journal of Haematology
|
June 15, 2021
Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant-ineligible patients with myeloma who are treated with bortezomib-based induction
Stephen Boyle, Cameron Wellard, Elizabeth M Moore, et al.
British Journal of Haematology
|
July 12, 2022
Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)
Zoe McQuilten, Cameron Wellard, Elizabeth Moore, et al.
Hemasphere
|
November 15, 2019
A Comparison of High-Dose Cytarabine During Induction Versus Consolidation Therapy in Newly Diagnosed AML
Anthony P Schwarer, Jason Butler, Kathryn Jackson, et al.
Bone Marrow Transplantation
|
May 20, 2021
Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR)
Krystal Bergin, Cameron Wellard, Bradley Augustson, et al.
Haematologica
|
September 30, 2021
Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14)
Anna Kalff, Tiffany Khong, Malarmathy Ramachandran, et al.
Internal Medicine Journal
|
August 5, 2025
Management of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation: position statement of the Medical and Scientific Advisory Group of Myeloma Australia
Georgia McCaughan, Hayley Beer, Christian Bryant, et al.
Internal Medicine Journal
|
April 24, 2023
Executive summary of consensus clinical practice guidelines for the prevention of infection in patients with multiple myeloma
Benjamin W Teh, Gemma Reynolds, Monica A Slavin, et al.
Pharmacoeconomics
|
October 29, 2025
A Post-Market Economic Evaluation of Bortezomib, Lenalidomide and Dexamethasone Versus Pre-funding Standard of Care for Newly Diagnosed Multiple Myeloma Using Registry Data
Adam Irving, Dennis Petrie, Anthony Harris, et al.
Page
of 15
Search research articles
Search
Showing results (91-100 of 145) with videos related to
Sort By:
Page
of 15
Heart, Lung & Circulation
|
April 3, 2024
2024 Australia-New Zealand Expert Consensus Statement on Cardiac Amyloidosis
Nicole K Bart, Diane Fatkin, James Gunton, et al.
The Clinical Biochemist. Reviews
|
July 26, 2021
Report of the Survey Conducted by RCPAQAP on Current Practices for Beta-Migrating Paraprotein Reporting
Joel D Smith, Nilika Wijeratne, Hans G Schneider, et al.
European Journal of Haematology
|
June 15, 2021
Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant-ineligible patients with myeloma who are treated with bortezomib-based induction
Stephen Boyle, Cameron Wellard, Elizabeth M Moore, et al.
British Journal of Haematology
|
July 12, 2022
Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)
Zoe McQuilten, Cameron Wellard, Elizabeth Moore, et al.
Hemasphere
|
November 15, 2019
A Comparison of High-Dose Cytarabine During Induction Versus Consolidation Therapy in Newly Diagnosed AML
Anthony P Schwarer, Jason Butler, Kathryn Jackson, et al.
Bone Marrow Transplantation
|
May 20, 2021
Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR)
Krystal Bergin, Cameron Wellard, Bradley Augustson, et al.
Haematologica
|
September 30, 2021
Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14)
Anna Kalff, Tiffany Khong, Malarmathy Ramachandran, et al.
Internal Medicine Journal
|
August 5, 2025
Management of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation: position statement of the Medical and Scientific Advisory Group of Myeloma Australia
Georgia McCaughan, Hayley Beer, Christian Bryant, et al.
Internal Medicine Journal
|
April 24, 2023
Executive summary of consensus clinical practice guidelines for the prevention of infection in patients with multiple myeloma
Benjamin W Teh, Gemma Reynolds, Monica A Slavin, et al.
Pharmacoeconomics
|
October 29, 2025
A Post-Market Economic Evaluation of Bortezomib, Lenalidomide and Dexamethasone Versus Pre-funding Standard of Care for Newly Diagnosed Multiple Myeloma Using Registry Data
Adam Irving, Dennis Petrie, Anthony Harris, et al.
Page
of 15